Pune, Sept. 24, 2020 (GLOBE NEWSWIRE) -- Advancements in stem cell research is a major driving factor for the global acute respiratory distress syndrome treatment market growth. According to the National Centre for Biotechnology Information (NCBI), 75% of the acute respiratory distress syndrome treatment (ARDS) cases are classified as severe and 8% of the mild cases progress to becoming moderate or severe. The overall mortality rate of ARDS is found to be at a shocking 43%.
Cell therapy has been found to be one of the potential solutions to the menace of ARDS, having benefits such as anti-bacterial action and lack of rejection molecules. The global acute respiratory distress syndrome treatment market revenue is being bolstered by the intensive research into stem cells. Private organizations are already pushing up their investments in this emerging field. For example, Japan-based HEALIOS K.K, recently acquired the rights to sell Multistem, a cell therapy product being researched for ARDS, commercially.
Highlights of the Report:
- Analysis of the impact of Covid-19 that the market would face in the near future.
- In-depth analysis of the growth drivers and obstacles.
- Profile of all the companies operating in the market.
- Elaborate data about the dominating region.
- Competitive landscape consisting of mergers & acquisitions, investments, partnerships, new product launches, opening of new facilities, and new contracts.
Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/acute-respiratory-distress-syndrome-treatment-market-101180
Fortune Business Insights shares critical market analysis in its report, titled “Acute Respiratory Distress Syndrome Treatment Market Size, Share and Global Trend By Drug Class (Vasoconstrictors, Bronchodilators, Steroids and Antibiotics, Nitric Oxide, Sedatives & Paralytics, Surfactant), By Route of Administration (Oral, Injection, Inhalation), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others) and Geography Forecast till 2026”. The report incorporates a bird’s eye-view and a worm’s eye-view evaluation of the factors that will shape the market in the forecast period as well as the emerging trends. Detailed assessment of regions, segments, and participants is also contained in the report.
Acute Respiratory Distress Syndrome (ARDS) is a severe pulmonary disorder which occurs when the air sacs in the lungs get filled with excess fluid. The result is that oxygen levels drop and carbon dioxide levels increase in the bloodstream. Organ failure is the ultimate effect of ARDS as organs do not get the required amount of oxygen to function. Common symptoms include dry cough, rapid pulse rate and breathing, headaches, and mental confusion. The most likely causes of ARDS are trauma to the chest or head, severe blood infection, other severe lung infection such as pneumonia, and inhalation of toxic substances such as chemicals and salt water.
The emergence of COVID-19 has brought the world to a standstill. We understand that this health crisis has brought an unprecedented impact on businesses across industries. However, this, too, shall pass. Rising support from governments and several companies can help in the fight against this highly contagious disease. Some industries are struggling, and some are thriving. Overall, almost every sector is anticipated to be impacted by the pandemic.
We are making continuous efforts to help your business sustain and grow during COVID-19 pandemics. Based on our experience and expertise, we will offer you an impact analysis of coronavirus outbreak across industries to help you prepare for the future.
Click here to get the short-term and long-term impact of COVID-19 on this Market.
Please visit: https://www.fortunebusinessinsights.com/industry-reports/acute-respiratory-distress-syndrome-treatment-market-101180
Increasing Demand for Neonatal Intensive Care Units (NICUs) to Drive the Market
According to statistics released by the American Thoracic Society, about 10% of the babies born prematurely in America develop Respiratory Distress Syndrome, also known as Hyaline Membrane Disease. As a result, the demand for neonatal ICUs is increasing at a considerable as about 12% of babies are born preterm in the US. This augurs well for the global acute respiratory distress syndrome treatment market size, which is slated for substantial expansion during the forecast period.
The only limiting factor for the global acute respiratory distress treatment market is the dearth of approved medicines for management of ARDS.
North America to Register High Growth; Asia-Pacific and Europe to Follow Suit
Among regions, North America is expected to grasp a major portion in the global acute respiratory distress syndrome treatment market share till 2026. The main reasons being development of new management guidelines for ARDS and advancements in alternative therapies. Asia-Pacific along with Europe is witnessing a steady rise in the number of ICUs and growing prevalence of ARDS. Latin America, Africa, and the Middle East are seen as promising regions with great business opportunities.
Have Any Query? Ask Our Experts: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/acute-respiratory-distress-syndrome-treatment-market-101180
Regulatory Approvals Build Confidence Among Market Players
The global acute respiratory distress syndrome treatment market stands to benefit from the fast-paced clearances from government authorities. For example, Athersys received a fast-track approval from the FDA for its MultiStem program to treat ARDS. Many companies are also carrying out advanced research and developing innovative products. For instance, Altor BioScience is conducting research on ALT-836, an antibody-based tissue factor antagonist, for treating ARDS caused by infections. These developments are anticipated to elevate the global acute respiratory distress syndrome treatment market potential.
Fortune Business Insights identifies the following players in the Acute Respiratory Distress Syndrome Treatment Market:
• Pfizer, Inc.
• Athersys Inc.
• Faron Pharmaceuticals, Ltd.
• GlaxoSmithKline plc.
• Teva Pharmaceuticals USA Inc.
• HEALIOS K.K.
Get your Customized Research Report: https://www.fortunebusinessinsights.com/enquiry/customization/acute-respiratory-distress-syndrome-treatment-market-101180
Acute Respiratory Distress Syndrome Treatment Market Segmentations:
By Drug Class
• Vasoconstrictors
• Bronchodilators
• Steroids and Antibiotics
• Nitric Oxide
• Sedatives & Paralytics
• Surfactant
• Others
By Route of Administration
• Oral
• Injection
• Inhalation
By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others
By Geography
• North America (USA and Canada)
• Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe)
• Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific)
• Latin America (Brazil, Mexico and Rest of Latin America)
• Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa)
Have a Look at Related Reports:
Medical Marijuana Market Share & Industry Analysis, By Application (Pain Disorders, Cancer, and Others), By Type (Flowers, Concentrates, Edibles and Others), By Distribution Channel (Dispensaries, Online Channel, and Others), and Regional Forecast, 2019-2026
Drug Eluting Stent (DES) Market Share & Industry Analysis, By Type (Coronary Stenting, and Peripheral Stenting), By Scaffold (Cobalt-Chromium, Platinum-Chromium, Nitinol and Others), By Drug (Sirolimus, Paclitaxel, Zotarolimus, Everolimus and Others), By End User (Hospitals, and Specialty Clinics), and Regional Forecast, 2019-2026
Biobanking Market Share & Industry Analysis, By Sample Storage (Blood, Cells & Tissue, and Others), By Application (Regenerative Medicines, Life Sciences, and Others), By Settings (Academic Medical Institutes, and Pharmaceutical & Biotechnology Companies), and Regional Forecast, 2019-2026
Cosmetic Surgery Market Share & Industry Analysis, By Type (Surgical Procedures, and Non-Surgical Procedures), By Gender (Males, and Females), By Providers (Spas & Cosmetic Surgery Centers, and Hospitals & Specialty Clinics), and Regional Forecast, 2019-2026
Wound Closure Market Share & Industry Analysis, By Product Type (Sutures, Hemostatic Agents, Staplers, Staples, and Others), By Application (Gynaecology, Cardiology, Orthopedics, Ophthalmic, General Surgery, and Others), By End User (Hospitals and Ambulatory Surgical Centers, Specialty Clinics, and Others), and Regional Forecast, 2019-2026
About Us:
Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.
Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.
At Fortune Business Insights™ we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.
Contact Us:
Fortune Business Insights™ Pvt. Ltd.
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune-Bangalore Highway,
Pune - 411045, Maharashtra, India.
Phone:
US :+1 424 253 0390
UK : +44 2071 939123
APAC : +91 744 740 1245
Email: sales@fortunebusinessinsights.com
Fortune Business Insights™
LinkedIn | Twitter | Blogs